Cilostazol suppresses neointimal hyperplasia in canine vein grafts

Fabio A. Kudo, Yuka Kondo, Akihito Muto, Keiko Miyazaki, Alan Dardik, Masayasu Nishibe, Toshiya Nishibe

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Purpose: To investigate whether cilostazol, a cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitor, suppresses intimal hyperplasia in canine vein grafts, and to elucidate its mechanisms in terms of cell proliferation and apoptosis. Methods: Bilateral reversed jugular vein interposition grafts of the common carotid artery were performed in 12 beagle dogs. Starting from 7 days before surgery, either cilostazol (30 mg/day; n = 6) or a placebo (n = 6) was given orally twice daily. Vein grafts were harvested at 1 or 4 weeks, and fixed under pressure for histological examination. Results: By 1 week after implantation, the cilostazol group showed significantly less cell proliferation than the placebo group. By 4 weeks after implantation, intimal and medial thickness was significantly thinner in the cilostazol group than in the placebo group. There was significantly more apoptosis in the placebo group than in the cilostazol group at both time points. Conclusion: Cilostazol suppressed the development of intimal hyperplasia in canine autogenous vein grafts. Thus, it may be associated with the modulation of cell proliferation and apoptosis.

Original languageEnglish
Pages (from-to)128-132
Number of pages5
JournalSurgery Today
Volume39
Issue number2
DOIs
Publication statusPublished - 02-2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Surgery

Fingerprint

Dive into the research topics of 'Cilostazol suppresses neointimal hyperplasia in canine vein grafts'. Together they form a unique fingerprint.

Cite this